- Home
- VRE vs DNLI Comparison
VRE vs DNLI Comparison
Compare VRE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- DNLI
- Stock Information
- Founded
- VRE 1949
- DNLI 2013
- Country
- VRE United States
- DNLI United States
- Employees
- VRE N/A
- DNLI N/A
- Industry
- VRE Real Estate Investment Trusts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRE Real Estate
- DNLI Health Care
- Exchange
- VRE Nasdaq
- DNLI Nasdaq
- Market Cap
- VRE 1.6B
- DNLI 1.9B
- IPO Year
- VRE 1994
- DNLI 2017
- Fundamental
- Price
- VRE $15.19
- DNLI $13.93
- Analyst Decision
- VRE Buy
- DNLI Strong Buy
- Analyst Count
- VRE 4
- DNLI 15
- Target Price
- VRE $18.50
- DNLI $33.85
- AVG Volume (30 Days)
- VRE 455.4K
- DNLI 1.4M
- Earning Date
- VRE 07-23-2025
- DNLI 07-31-2025
- Dividend Yield
- VRE 2.10%
- DNLI N/A
- EPS Growth
- VRE N/A
- DNLI N/A
- EPS
- VRE N/A
- DNLI N/A
- Revenue
- VRE $279,630,000.00
- DNLI N/A
- Revenue This Year
- VRE $0.12
- DNLI N/A
- Revenue Next Year
- VRE $2.42
- DNLI $256.73
- P/E Ratio
- VRE N/A
- DNLI N/A
- Revenue Growth
- VRE 3.92
- DNLI N/A
- 52 Week Low
- VRE $13.84
- DNLI $10.57
- 52 Week High
- VRE $18.85
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- VRE 46.78
- DNLI 48.84
- Support Level
- VRE $14.81
- DNLI $12.86
- Resistance Level
- VRE $15.29
- DNLI $13.77
- Average True Range (ATR)
- VRE 0.31
- DNLI 0.74
- MACD
- VRE 0.01
- DNLI -0.00
- Stochastic Oscillator
- VRE 60.71
- DNLI 61.49
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.